Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP) - Assessment of corresponding epitopes

Clinical Biochemistry

Volumn 43, Issue 15, 2010, Pages 1249-1256

  Leeming, D J ^a,c   Larsen, D V ^a   Zhang, C ^b   Hi, Y ^b   Veidal, S S ^a   Nielsen, R H ^a   Henriksen, K ^a   Zheng, Q ^b   Barkholt, V ^c   Riis, B J ^d   Byrjalsen, I ^a   Qvist, P ^a   Karsdal, M A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b Nordic Bioscience Beijing   (China)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d Nordic Bioscience Clinical Studies A/S   (Denmark)

Author keywords

BDL; Biochemical markers; Bone formation; Ibandronate; OVX; PINP; Translational science

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN; EPITOPE; IBANDRONIC ACID; MONOCLONAL ANTIBODY; N TERMINAL COLLAGEN TYPE 1 PROPEPTIDE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GOLD STANDARD; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN TARGETING; RAT;

AGED; AMINO ACID SEQUENCE; ANIMALS; BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CALIBRATION; CLONE CELLS; DEMOGRAPHY; DIPHOSPHONATES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HUMANS; MOLECULAR SEQUENCE DATA; OSTEOCALCIN; OVARIECTOMY; PEPTIDE FRAGMENTS; PLACEBOS; POSTMENOPAUSE; PROCOLLAGEN; RATS;

EID: 77956775667     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.07.025     Document Type: Article

References (40)

1. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science 2000, 289:1508-1514.
2. Horowitz M.C., Xi Y., Wilson K., Kacena M.A. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 2001, 12:9-18.
3. Karsdal M.A., Henriksen K., Leeming D.J., Mitchell P., Duffin K., Barascuk N., et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009, 14:181-202.
4. Schaller S., Henriksen K., Hoegh-Andersen P., Sondergaard B.C., Sumer E.U., Tanko L.B., et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?. Assay Drug Dev Technol 2005, 3:553-580.
5. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994, 40:2022-2025.
6. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
7. Cloos P.A., Lyubimova N., Solberg H., Qvist P., Christiansen C., Byrjalsen I., et al. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Clin Lab 2004, 50:279-289.
8. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993, 39:635-640.
9. Melkko J., Kauppila S., Niemi S., Risteli L., Haukipuro K., Jukkola A., et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996, 42:947-954.
10. Garnero P., Ferreras M., Karsdal M.A., NicAmhlaoibh R., Risteli J., Borel O., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003, 18:859-867.
11. Garnero P., Delmas P.D. New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996, 59(Suppl 1):S2-S9.
12. Gefter M.L., Margulies D.H., Scharff M.D. A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet 1977, 3:231-236.
13. Veidal SS, Vassiliadis E, Barascuk N, Zhang C, Segovia-Silvestre T, Klickstein L, Larsen M.R., Qvist P, Christiansen C, Vainer B, Karsdal MA. MMP-9 mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int. 2010 Jul 19 [Epub ahead of print]. doi:10.1111/j.1478-3231.2010.02309.x.
14. Riis B.J., Ise J., von S.T., Bagger Y., Christiansen C. Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001, 16:1871-1878.
15. Bagger Y.Z., Tanko L.B., Alexandersen P., Karsdal M.A., Olson M., Mindeholm L., et al. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 2005, 37:425-430.
16. Delmas P.D., Recker R.R., Chesnut C.H., Skag A., Stakkestad J.A., Emkey R., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004, 15:792-798.
17. Garnero P., Cloos P., Sornay-Rendu E., Qvist P., Delmas P.D. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res 2002, 17:826-833.
18. Reid I.R., Miller P., Lyles K., Fraser W., Brown J.P., Saidi Y., et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005, 353:898-908.
19. Alexandersen P., Peris P., Guanabens N., Byrjalsen I., Alvarez L., Solberg H., et al. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. J Bone Miner Res 2005, 20:588-595.
20. Leeming D.J., Koizumi M., Byrjalsen I., Li B., Qvist P., Tanko L.B. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev 2006, 15:32-38.
21. Jung K., Lein M., Stephan C., Von Hosslin K., Semjonow A., Sinha P., et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004, 111:783-791.
22. Diaz-Martin M.A., Traba M.L., De La P.C., Guerrero R., Mendez-Davila C., De La Pena E.G. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma. Scand J Clin Lab Invest 1999, 59:125-132.
23. Kataoka A., Yuasa T., Kageyama S., Tsuchiya N., Habuchi T., Iwaki H., et al. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen. Clin Oncol (R Coll Radiol) 2006, 18:480-484.
24. Ravn P., Clemmesen B., Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999, 24:237-244.
25. Adami S., Passeri M., Ortolani S., Broggini M., Carratelli L., Caruso I., et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995, 17:383-390.
26. Garnero P., Grimaux M., Demiaux B., Preaudat C., Seguin P., Delmas P.D. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res 1992, 7:1389-1398.
27. Reginster J.Y., Sarkar S., Zegels B., Henrotin Y., Bruyere O., Agnusdei D., et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004, 34:344-351.
28. Orum O., Hansen M., Jensen C.H., Sorensen H.A., Jensen L.B., Horslev-Petersen K., et al. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 1996, 19:157-163.
29. Ettinger B., San Martin J., Crans G., Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745-751.
30. Linkhart S.G., Linkhart T.A., Taylor A.K., Wergedal J.E., Bettica P., Baylink D.J. Synthetic peptide-based immunoassay for amino-terminal propeptide of type I procollagen: application for evaluation of bone formation. Clin Chem 1993, 39:2254-2258.
31. Hale L.V., Galvin R.J., Risteli J., Ma Y.L., Harvey A.K., Yang X., et al. PINP: a serum biomarker of bone formation in the rat. Bone 2007, 40:1103-1109.
32. Kauppila S., Tekay A., Risteli L., Koivisto M., Risteli J. Type I and type III procollagen propeptides in amniotic fluid of normal pregnancies and in a case of mild osteogenesis imperfecta. Eur J Clin Invest 1998, 28:831-837.
33. Brandt J., Krogh T.N., Jensen C.H., Frederiksen J.K., Teisner B. Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology. Clin Chem 1999, 45:47-53.
34. Delmas P.D. Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am 1990, 19:1-18.
35. Leeming D.J., Hegele A., Byrjalsen I., Hofmann R., Qvist P., Karsdal M.A., et al. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers. Cancer Epidemiol Biomarkers Prev 2008, 17:1269-1276.
36. Iqbal S.J., Davies T., Holland S., Manning T., Whittaker P. Alkaline phosphatase isoenzymes and clinical features in hypophosphatasia. Ann Clin Biochem 2000, 37(Pt 6):775-780.
37. Rissanen J.P., Suominen M.I., Peng Z., Morko J., Rasi S., Risteli J., et al. Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model. Calcif Tissue Int 2008, 82:155-161.
38. Schytte S., Hansen M., Moller S., Junker P., Henriksen J.H., Hillingso J., et al. Hepatic and renal extraction of circulating type I procollagen aminopropeptide in patients with normal liver function and in patients with alcoholic cirrhosis. Scand J Clin Lab Invest 1999, 59:627-633.
39. Veidal S.S., Bay-Jensen A.C., Vainer B., Tougas G., Karsdal M.A. N-terminal Propeptide of Type I Collagen is a Marker for Fibrogenesis in BIle Duct Ligation-Induced Fibrosis in Rats 2010.
40. Rodan G.A. Mechanical loading, estrogen deficiency, and the coupling of bone formation to bone resorption. J Bone Miner Res 1991, 6:527-530.